KnE Life Sciences | The 1st International Conference on Health, Technology and Life Sciences (ICO-HELICS) | pages: 30–35

, , and

1. Introduction

Diet containing high fat and fructose increases the secretion of very low density lipoprotein (VLDL), causing hypercholesterolemia and hypertriglyceridemia, which are the symptoms of a lipid metabolism disorder called hyperlipidemia [1]. The mechanism of hyperlipidemia starts with the liver secreting VLDL which transports triglyceride to peripheral tissues [2]. Triglyceride is hydrolyzed by lipase lipoprotein, producing free fatty acids (FFA) to be stored in tissues such as healthy muscles and skeletal muscles [3]. The higher the triglyceride level, the higher the FFA level, which can induce an inflammatory response [4]. FFA bind to Toll-like receptor 2 (TLR 2) and Toll-like receptor 4 (TLR 4) which induce nuclear factor kappa β (NFkβ) to secrete proinflammatory cytokines such as IL-1β [5]. FFA also stimulate the activation of NOD-like receptor protein 3 (NLRP3) which will activate Caspase-1 [6], then Caspase-1 will turn pro IL-1β into IL-1β [7].

Interleukin 1β is a proinflammatory cytokine which has a broad spectrum of immunological activity [8]. IL-1β production is regulated by 2 mechanisms; i.e., TLR activation and activation by NLRP3 inflammasome [9]. The first mechanism through activated TLR, especially TLR 2 and TLR 4, will trigger the activation of NFkβ, then NFkβ secretes proinflammatory cytokine such as IL-1β [10]. The second mechanism through NLRP3 inflammasome complex produces pro-Caspase 1 and is activated into Caspase-1 [11]. Caspase-1 activates pro-IL-1β into active and mature IL-1β. The secretion of IL-1β is induced by NFkβ transcription factor [12]. NFkβ and production of inflammatory cytokines such as IL-1β can be suppressed by short-chain fatty acids (SCFA) [13].

Short chain fatty acids are formed when food fiber is fermented by anaerobic bacteria in the large intestines [14]. Short chain fatty acids affect 3 signaling pathways, which are G-protein receptor (GPR) activation [15], histone deacetylase (HDAC) inhibition, and histone acetyltransferase (HAT) activation [16]. Activation of the GPR pathway, especially GPR41 and GPR43, is important for the expression of inflammatory mediators such as IL-1β [13]. The main SCFAs produced in human intestines are butyrate, propionate, and acetate [17]. Butyrate can inhibit the activation of NFkβ transcription factor [18]. Butyrate and propionate can suppress the secretion of IL-1β through HDAC inhibition mechanisms [19]. The present study investigated the effect of high fiber diet on the level and expression of IL-1β in high fat and fructose diet of Wistar rats.

2. Material and Methods

This study was conducted on eight weeks old Wistar strain male rats (Rattusnorvegicus) with a body weight of 150-200 grams. The rats were obtained from Biofarma, and acclimatized for one week in room temperature with access to water and food ad libitum. The rats (n=25) were divided into five groups. Each group consisted of 5 rats. One group of rats as a control group (K) was given standard rat food (AIN-93M), while four groups of rats were given high-fat and fructose diet. One group of high-fat and fructose diet rats received no high-fiber diet (Hyperlipidemia group [D]), while three groups received high-fiber diet in different doses of 2.6 g/rat/day (P1), 5.2 g/rat/day (P2) and 7.8 g/rat/day (P3). A high-fiber diet was formed in pellets and given orally for 6 weeks.

Pretest serum levels of IL-1β was taken at the 7th week of treatment and the posttest serum levels of IL-1β was taken at the end of 13 weeks of this protocol. Three milliliters blood were collected from medial canthus orbital sinus to determine pretest and posttest serum levels of IL-1β (Fine test) with ELISA methods.

The protocol of this study was approved by the Medical and Health Research Ethics Committee of the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta (Reg.00065/04/LPPT/VI/2017). Data were presented as mean ± standard deviation (SD). Statistical analysis of serum levels of IL-1β was performed using paired-t test, using a value of p < 0.05 as statistically significant.

3. Results

Serum levels of IL-1β during pretest and posttest are shown in Figure 1. In hyperlipidemia rats (D), the IL-1β levels were significantly higher compared to control rats (K), and were also significantly higher compared to the hyperlipidemia rats which received different doses of high-fiber diet (p < 0.05). The levels of IL-1β in hyperlipidemia rats which received the high-fiber diet were significantly lower compared to hyperlipidemia rats (D) and control rats (K), and there were no significant differences between hyperlipidemia rats which received a high-fiber diet in different doses (P1, P2, and P3).

Figure 1

Pretest and Posttest Serum Level of Interleukin 1 β in Rats. Data is displayed as Mean ± Standard Deviation (SD), * stated p < 0.05 in paired-t test. p < 0.05 is categorized as a significant value. K: Normal control group; D: Hyperlipidemia group; P1: Hyperlipidemia + fiber 2.6 g/rat/day; P2: Hyperlipidemia + fiber 5.2 g/rat/day; P3: Hyperlipidemia + fiber 7.8 g/rat/day.


4. Discussion

This study showed that increased levels of IL-1β occurred in rats with hyperlipidemia. This finding demonstrated that high fat and fructose diet could induce inflammation characterized by increased levels of IL-1β. It was in line with previous studies which report that high fat and fructose diet can lead to inflammation characterized by high levels of IL-1β [20]. Higher inflammatory response showed higher level of IL-1β [21], due to activation of inflammasomes, increased translocation of nNFkβ to the nucleus, and increased secretion of cytokines [22]. Increased levels of IL-1β were caused by rising FFA, which included TLR2 and TLR4. Free fatty acids bind to their receptors triggering degradation Inhibitor Kinase Kappa β (IKKβ) [23].

The research result showed that a high fiber diet could reduce the level of IL-1β. It was in line with the previous study which states that a high fiber diet can reduce inflammatory responses characterized by lower IL-1β [24]. It was suspected to be due to SCFA contents, especially butyrate, one of the results of fermentation of food fiber, suppressing cytokines which stimulate the production of inflammatory mediators such as IL-1β [25]. The main mechanism which could explain the effect was reduced HDAC activity [26]. Butyrate was the most potent HDAC inhibitor compared with acetate[26]. Histone deacetylase and HAT control the level of protein acetylation. Butyrate inhibits HDAC activity, thus increasing histone and non-histone protein acetylation, including NFκB, prevented the activation of NFκB [18]. Prevention of NFκB activation also plays a role in preventing the release of proinflammatory cytokines such as IL-1β [27].

Reduction of IL-1β level in rats given 5.2 g/rat/day fiber was higher than rats given fiber 2.6 g/rat/day, while in rats given fiber 7.8 g/rat/day it was lower than rats given fiber 2.6 g/rat/day. The result was in line with the previous study that showed relatively adequate dosage of fiber when increased to double dose increases fermentation product in the form of SCFA, including butyrate [28]. Short chain fatty acids worked with cytokines in leukocytes and endothelial cells through two mechanisms, i.e. GPR activation HDAC inhibition [25]. Short chain fatty acids regulated cytokine production, including IL-1β[13]. Microflora in the intestines and SCFA were interconnected and depend on each other. To be able to produce SCFA in the gastrointestinal tract, there should be microbes which produce enzymes for fermentation of resistant starch which could be digested by human digestion [28]. As a result, the number of microflora also could affect the amount of SCFA production [29]. As a consequence, increasing dietary fiber dosage did not always increase ability in reducing IL-1β level, depending on the number of microflora in the colon. High fiber diet could reduce the level of triglycerides and level of IL-1β in hyperlipidemia rats, especially at 5.2 grams fiber/day.


The author would like to thank the Faculty of Medicine, Public Health, and Nursing of Universitas Gadjah Mada for assistance in this study and the Indonesia Endowment Fund for Education (LPDP) of the Ministry of Finance of the Republic of Indonesia through Excellence Scholarship for Domestic Indonesian Lecturer (BUDI-DN) for funding this study.



Maithilikarpagaselvi M, Sridhar M G, Swaminathan R P, Sripradha R and Badhe B 2016 Pharm Biol. 54 2857-63


Klop B, Elte J W F and Cabezas M C 2013 Nutrients 5 1218-40


Evans K, Burdge G C, Wootton S A, Clark M L and Frayn K N 2002 Diabetes 51 2684-90


Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H and Aljada A 2003 Diabetes 52 2882-7


Huang S, Rutkowsky J M, Snodgrass R G, Moore K D O, Schneider D A and Newman J A 2012 J Lipid Res. 53 2002-13


Luo Z L, Ren J D, Huang Z, Wang T, Xiang K, and Cheng L 2017 Cell Physiol Biochem. 42 1635-44


Brough D, and Rothwell N J 2007 J. Cell Sci. 120 772-81


Schnetzler B M, Boller S, Debray S, Bouzakri K, Meier D T and Prazak R 2009 Endocrinology 150 5218-29


He Y, Hara H, and Nunez G 2016 Cell 41 1012-21


Agostino L, Martinon, F, Burns K, McDermott M F, Hawkins P N and Tschopp J 2004 Immunity 20 319-25


Church L D, Cook G P, and McDermott M F 2008 Nat Clin Pract Rheumatol. 4 34-42


Ren K and Torres R 2009 Brain Res. 60 57-64


Kim M H, Kang S G, Park J H, Yanagisawa M and Kim C H 2013 Gastroenterology 145 396-406


Macia L, Tan J, Vieira A T, Leach K, Stanley D, and Luong S 2015 Nat Commun. 6 6734


Comalada M, Bailon E, de-Haro O, Lara-Villoslada F, Xaus J and Zarzuelo A 2006 J Cancer Res Clin Oncol. 132 487-97


Donohoe D R, Collins L B, Wali A, Bigler R, Sun W and Bultman S J 2001 Mol Cell. 48 612-26


Hurst N R, Kendig D M, Murthy K S and Grider J R 2014 J Neurogastroenterol Motil. 26 1586-96


Segain J, de la Bletiere D R, Bourreille A, Leray V, Gervois N and Rosales C 2000 Gut. 47 397-403.


Canani R B, Costanzo M D, Leone L, Pedata M, Meli R and Calignano A 2011 World J Gastroenterol. 17 1519–28


Ochoa E C, Ortega K H, Ferrera P, Morimoto S and Arias C 2014 J Cereb Blood Flow Metab. 34 1001-08


Dinarello C A 2011 Blood 117 3720-32


Bauernfeind F, Horvath G, Stutz A, Alnemri E S, MacDonald K and Speert D 2009 J Immunol. 183 787-91


Israel A 2010 Cold Spring Harb Perspect Biol. 2 a000158


Morrison D J and Preston T 2016 J Gut Microbes.7 189-200


Ohira H, Fujioka Y, Katagiri C, Yano M, Mamoto R and Aoyama M 2012 J Clin Biochem Nutr. 50 59-66


Chang P V, Hao L, Offermanns S and Medzhitov R 2014 Proc Natl Acad Sci. 111 2247-52


McKenna S, Butler B, Jatana K, Ghosh S and Wright C J 2017 Pediatr Res. 82 1064-72


Morrison D J and Preston T 2016 Gut Microbes. 7 189-200


Besten G D, Eunen K V, Groen A K, Venema K D, Reijngoud K J and Bakker B M 2013 J Lipid Res. 54 2325-40



  • Downloads 4
  • Views 22



ISSN: 2413-0877